Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects

NCT ID: NCT04285554

Last Updated: 2023-03-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-28
• Study Completion Date: 2022-12-19

Brief Summary

The objective of this early feasibility study is to evaluate the safety and performance of intravascular hepatic denervation using the Metavention Integrated Radio Frequency Denervation System (iRF System) to improve glycemic control in type 2 diabetes subjects.

Conditions

Diabetes Mellitus, Type 2

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DEVICE_FEASIBILITY
• Blinding Strategy: NONE

Study Groups

Hepatic Denervation

Group Type: EXPERIMENTAL

iRF System Hepatic Denervation

Intervention Type: DEVICE

The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the common hepatic artery (CHA).

Interventions

iRF System Hepatic Denervation

The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the common hepatic artery (CHA).

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age ≥22 and ≤70 years old

2. Type 2 diabetes diagnosis meeting the following criteria:

1. HbA1c > 7.0% and ≤ 9.0% (53 mmol/mol - 75 mmol/mol), AND

2. On at least two anti-diabetic medications; one at the highest tolerated dose with no changes in medication dose in the 12 weeks prior to the first screening visit

3. Waist circumference ≥102 cm (male) and ≥88cm (female)

4. Diagnosis of hypertension: SBP ≥140mmHg OR SBP ≥130mmHg on hypertension medication(s)

5. Documented status of stable lifestyle modifications

6. Women of childbearing potential (WOCBP) must be using at least one acceptable method of contraception throughout the study

Exclusion Criteria

1. BMI >40 kg/m2

2. Diagnosis of type 1 diabetes

3. Use of insulin within 90 days of consent

4. Two or more self-reported or documented severe hypoglycemia events (severe hypoglycemia event defined as: hypoglycemia associated with severe cognitive impairment requiring external assistance for recovery) in the 180 days prior to Index Procedure

5. One or more documented hyperglycemia episodes requiring hospitalization in the 180-days prior to Index Procedure

6. During medication run in period, uncontrolled hyperglycemia noted by a fasting glucose value of >270mg/dL or >360mg/dL at any point that is then confirmed by a second measurement (not on the same day)

7. A history of bariatric surgery, renal denervation, baroreflex activation therapy, or liver transplant, or these procedures are planned in the 365 days following Index Procedure

8. Any surgical procedure within 30 days prior to Index Procedure

9. History of or current symptomatic gallstones (e.g., cholecystitis, bile duct dilatation) without a cholecystectomy being performed (Note: subjects who have had a cholecystectomy are not excluded)

10. Previous hepatobiliary surgery/intervention that in the opinion of the investigator could preclude the ability to perform denervation of the common hepatic artery

11. Currently taking the following medications within 90 days prior to screening and/or there is a need or anticipated need for these medications during the study:

1. Systemic corticosteroids

2. Anticonvulsants

3. Centrally acting sympatholytics

12. Use of anticoagulation therapy which cannot be discontinued from 7 days before to 14 days after the Index Procedure

13. Any other condition(s) that would compromise the safety of the Subject or compromise study quality as judged by the Investigator

14. eGFR <45 mL/min/1.73 m2

15. History or diagnosis of proliferative retinopathy or advanced autonomic neuropathy (e.g., orthostatic hypotension attributable to autonomic neuropathy, a diagnosis of gastroparesis, or a clinical history strongly suggestive of delayed gastric emptying)

16. Myocardial infarction, unstable angina within 1 year prior to consent

17. Widespread atherosclerosis with documented intravascular thrombosis or unstable plaques

18. Documented history or concurrent signs of significant thyroid disease NOTE: If a subject is on chronic thyroid drug treatment, and has a serum TSH test result in normal range at Screening they may enter study

19. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count <100,000/microliter, or documented coagulopathy

20. Significant alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to reliably quantify alcohol intake

21. Active substance abuse, based on Investigator judgment, including inhaled or injected drugs, within 1 year prior to the initial screening

22. Significant weight loss within the last 6 months (e.g., >10% total body weight loss)

23. Hepatic decompensation defined as the presence of any of the following:

1. Serum albumin less than 3.5 g/dL

2. International normalized ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants)

3. Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome

4. History of esophageal varices, ascites, or hepatic encephalopathy

24. ALT or AST greater than 200 U/L

25. Diagnosis of liver cirrhosis

26. Chronic liver or biliary disease of the following etiology:

1. History or diagnosis of Hepatitis B

2. History or diagnosis of Hepatitis C

3. History or diagnosis of current active autoimmune hepatitis

4. History or diagnosis of primary biliary cholangitis (PBC)

5. History or diagnosis of primary sclerosing cholangitis

6. History or diagnosis of Wilson's disease

7. History or diagnosis of alpha-1-antitrypsin deficiency

8. History or diagnosis of hemochromatosis

9. History or evidence of drug-induced liver disease, as defined on the basis of typical exposure and history

10. Known bile duct obstruction

11. Suspected or proven liver cancer

27. History of acute or chronic pancreatitis

28. Subjects unable to undergo CT for any reason

29. Currently enrolled in any other investigational trial

30. History of an acute neurologic event including epilepsy, seizures, stroke, and transient ischemic attack.

31. Iliac/femoral artery stenosis precluding insertion of the catheter

32. Human immunodeficiency virus (HIV)

33. Subjects with a history of adverse reaction to heparin or heparin induced thrombocytopenia (HIT)

34. Subjects with conditions that can affect RBC turnover, those who have received a blood transfusion in the past 90 days, or expect to have an elective procedure during the course of the study that may require blood transfusion

35. Not a candidate for surgery or general anesthesia

36. Unwilling to comply with study requirements, including medication run-in, SMBG, patient diary and follow-up visits

37. Subjects with implantable pacemakers, implantable cardiac defibrillators or implantable neurostimulators

Anatomic Exclusions from CT Angiogram

38. Replaced or accessory LHA or RHA determined on CT angiogram.

39. Vessel tortuosity or variant vascular anatomy that could preclude the access or maneuvering of the device from the femoral artery to the target location

40. Evidence of CHA and/or portal vein intraluminal thrombus

41. CHA vessel diameter <4.0mm or >7.0mm

42. CHA diameter stenosis >30%

43. CHA vessel length <20mm

• Minimum Eligible Age: 22 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Metavention

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Cardiology, P.C.

Birmingham, Alabama, United States

Stanford University Medical Center

Stanford, California, United States

AdventHealth Translational Research Institute

Orlando, Florida, United States

Prairie Education & Research Cooperative (PERC)

Springfield, Illinois, United States

Metropolitan Cardiology Consultants

Coon Rapids, Minnesota, United States

South Oklahoma Heart Research, LLC

Oklahoma City, Oklahoma, United States

UPMC Pinnacle

Harrisburg, Pennsylvania, United States

Soltero Cardiovascular Research Center

Dallas, Texas, United States

Countries

United States

Other Identifiers

932

Identifier Type: -

Identifier Source: org_study_id